Senate inquiry into Avandia safety puts GSK in the hot seat
22 February 2010
Asher Mullard
A US Senate inquiry into GlaxoSmithKline's Avandia (rosiglitazone) has found that the drug is needlessly hazardous and has accused the UK company of deliberately misleading physicians and the public over the safety profile of its much-beleaguered, once-blockbuster anti-diabetic.
...
Please Login to read the full article.
22 February 2010
Asher Mullard
...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA, GSK put Avandia pharmacy exit plan in place
- US Capitol Capsule: Obama wants one-stop shop for patents, trade & small biz aid
- Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide
- US Capitol Capsule: IOM analysis finds little evidence of vaccine harm, debunks autism link
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
